Biocortech

Biocortech was established in November 2001 to commercialize the fruits of the founders' research into the underlying causes of treatment-resistant forms of CNS diseases such as depression and schizophrenia. The company's aim is to develop effective therapies for these and other diseases associated with the pre-frontal cortex of the brain, such as bipolar disorder and cognitive and sexual disorders.

Jean François Pujol, MD, PhD, and Dinah Weissmann, PhD, founded Biocortech in November 2001 to commercialize the fruits of their research into the underlying causes of treatment-resistant forms of CNS diseases such as depression and schizophrenia. The scientists, whose research was conducted at the CNS research unit of the French National Research Center (CNRS) in Lyons, aim to develop effective therapies for these and other diseases associated with the pre-frontal cortex of the brain, such as bipolar disorder and cognitive and sexual disorders.

It's well recognized that deficiencies in neurotransmitter levels and/or neurotransmitter receptor expression or functioning perturb normal signalling through the neuronal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.